Caribou Biosciences, Inc. (CRBU) Stock

Caribou Biosciences, Inc. (CRBU) is a Healthcare stock trading at $1.65 (as of 2026-08-21), with a market capitalization of $176.89M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Caribou Biosciences develops genome-edited, allogeneic cell therapies, including CAR-T and CAR-NK candidates, aimed at treating hematologic malignancies and solid tumors in the United States and internationally. Its programs include CB-010 for relapsed/refractory B-cell non-Hodgkin lymphoma, CB-011 for relapsed/refractory multiple myeloma, CB-012 for relapsed/refractory acute myeloid leukemia, and CB-020 for solid tumors.

Understand Caribou Biosciences, Inc.: how it makes money

Caribou Biosciences develops genome-edited, allogeneic cell therapies for cancer, with lead candidates CB-010 (anti-CD19 CAR-T) and CB-011 (anti-BCMA CAR-T), and it makes money through licensing and collaboration revenue (currently reported as 0.0B in the latest quarter).

For a clinical-stage biopharmaceutical company like Caribou, the path to revenue depends on advancing programs enough to generate licensing and collaboration income and, later, commercialization; in the latest quarter, licensing and collaboration revenue is reported as 0.0B.

Revenue by segment (latest quarter)
Lic/Collab	$0.0B

Business quality (Weak): Latest reported quarter shows no licensing and collaboration revenue, so investors are mainly focused on clinical execution signals, such as response rates and safety events, from early stage CAR-T programs.

Bull case

Clinical response signals: Reported Overall Response Rate is 92% and Complete Response Rate is 75%, based on the available operating KPI set.
Active clinical progress with CAR-T programs: The company reports patient enrollment and cohort work in phase 1 programs, including 84 patients treated in the ANTLER Phase 1 Clinical Trial and a 12 patient CB-011 cohort size.

Bear case

Safety risk remains a key uncertainty: The operating KPIs show Grade 3 or Higher Infections Incidence at 22% and Grade 3 or Higher Prolonged Cytopenias Incidence at 21%, alongside other Grade 3 or Higher event rates.
No current licensing and collaboration revenue: Licensing and Collaboration Revenue is reported as 0.0B in the latest quarter, so near term non-trial funding signals are not captured in the provided financial segment data.
Early stage development risk: Lead candidates CB-010 and CB-011 are described as being in phase 1 clinical trial, which typically means outcomes and scalability are not yet fully established.

Valuation — source: SEC EDGAR (first-party)
Price	$1.65
Market Cap	$176.89M
Price / Book	1.80
Price / Sales	20.83
FCF Yield	-110.6%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$11.16M
Net Margin	-1327.4%
Revenue Growth (YoY)	11.7%
EPS Growth (YoY)	-3.6%
FCF Growth (YoY)	-21.5%

Financial Health — source: SEC EDGAR
Altman Z-Score	-4.87 (distress)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.2

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Pfizer Inc ($8.35M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Rachel E. Haurwitz
Employees	147
Country	US
IPO Date	2021-07-23

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.